TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07916194: A Phase I Clinical Study to Evaluate the Pharmacokinetic Characteristics and Safety of Single Dose of Zovaglutide (ZT002 Injection) in Participants With Varying Degrees of Hepatic Impairment and Matched Participants With

Sponsor: Beijing QL Biopharmaceutical Co.,Ltd · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 24 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$3,770,192

Rescue Site Savings

+$2,483,360

Unlock Full NCT07916194 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07916194 Rescue Dossier →